Similarly, Guo et al. emphasized that PACAP38 plays a distinct and significant role in migraine pathophysiology, operating independently from the CGRP pathway and offering a potential therapeutic target, particularly for patients unresponsive to CGRP-based treatments. This evidence concerns the gene ADCYAP1 and migraine disorder.